Interest is growing in discussions by the Ministry of Health, Labor and Welfare’s (MHLW) new expert panel on comprehensive pharmaceutical measures. At its meeting on September 22, major trade groups made their cases to push for a re-think of the…
HOME > REGULATORY
REGULATORY
- Guidelines for Securing Key Resources Endorsed by LDP, Up for Cabinet Approval
July 20, 2022
- MHLW Official Sees More “Specified Clinical Research” Data Used in Regulatory Submissions to Fill Industry-Academia Void
July 20, 2022
- PMDA Head Fujiwara Re-Elected as ICMRA Vice Chair
July 20, 2022
- Taisho/Ablynx’s RA Med, BI’s Psoriasis Drug Up for MHLW Panel Review on July 29
July 19, 2022
- Japan Panel to Discuss 4th COVID Shot to Healthcare Providers: Health Minister
July 19, 2022
- MHLW Eyes Expert Panel Launch This Summer for Drug Distribution and Pricing: Official
July 19, 2022
- Japan Plans to Lower Minimum Age for Novavax Jab to 12
July 19, 2022
- MHLW Mulls Data Collection Policy for Conditionally Approved MSC Therapies
July 14, 2022
- Shionogi’s COVID-19 Pill Up for Expert Redeliberation on July 20
July 14, 2022
- Govt Council Calls for Steps to Beef Up Japan’s Clinical Trial System for Vaccines
July 13, 2022
- Accelerate Social Implementation of Genomic Medicine: Study Group
July 13, 2022
- 92 Defects/Health Damages Reported for Kymriah in October-March
July 13, 2022
- All 10 Pharma-Backed Candidates Grab Upper House Seats
July 12, 2022
- Japan Detects 4 More Probable Cases of Pediatric Hepatitis
July 11, 2022
- After Abe’s Death, Pharma and Medical Circles Fret Shift to Austerity and Tougher Drug Pricing
July 11, 2022
- No Major Safety Concerns for COVID-19 Vaccines in Japan: MHLW Panels
July 11, 2022
- Label Revision Ordered for Novavax Jab to Add Myocarditis Risks
July 11, 2022
- Drug Makers Can Now Access MID-NET from Their Own Offices
July 11, 2022
- Japan to Discuss Fourth COVID Shot for Below Age 60: Govt Official
July 8, 2022
- Tokyo Entered Seventh Wave of COVID-19: Experts
July 8, 2022
ページ
Healthcare in the US is a highly political topic, with one end of the political spectrum arguing for broader government-sponsored access and the other advocating for more of a free-market approach. While the US market has typically been the primary…
The average ratio of females in managerial posts at Japanese drug makers has finally reached a double-digit number, at 10.0%, a Jiho survey found. However, this is still well below a near-25% ratio logged by foreign players operating in the…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…
A total of 15 new drugs (APIs) joined the NHI price list in 2021 with peak sales forecasts topping at 10 billion yen, many of them in the area of orphan diseases and with few mega launches, according to a…